Vibha Kumari

Vibha Kumari

Auto-generated profile, based on publicly available information

Vibha Kumari

Department of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura (U.P.), India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2024 in Pharmacological Research - Modern Chinese Medicine
Verified
Journal Article
Open access
SBSonal Bansal
Sonal Bansal
KPKm Pratiksha
Km Pratiksha
RGRishabh Gaur
Rishabh Gaur
SGSomya Gupta
Somya Gupta
VJVed Prakash Jadaun
Ved Prakash Jadaun
VKVibha Kumari
Vibha Kumari

1 July 2024 in Current Cardiology Reviews
Verified
Journal Article
Closed access
PDF file
ARAnamika Rathore
Anamika Rathore
ASAnuj Kumar Sharma
Anuj Kumar Sharma
YMYogesh Murti
Yogesh Murti
SBSonal Bansal
Sonal Bansal
VKVibha Kumari
Vibha Kumari
MKMayank Kulshreshtha
Mayank Kulshreshtha
Background: Myocardial infarction (MI), also referred to as a "heart attack," is brought on by a partial or total interruption of blood supply to the myocardium. Myocardial infarction can be "silent," go undiagnosed, or it can be a catastrophic occurrence that results in hemodynamic decline and untimely death. In recent years, herbal remedies for MI have become effective, secure, and readily accessible. Objective: The purpose of this review was to examine the medicinal plants and phytochemicals that have been used to treat MI in order to assess the potential contribution of natural substances to the development of herbal MI treatments. Methodology: A literature search was employed to find information utilizing electronic databases, such as Web of Science, Google Scholar, PubMed, Sci Finder, Reaxys, and Cochrane. Results: The identification of 140 plants from 12 families led to the abstraction of data on the plant families, parts of the plant employed, chemical contents, extracts, model used, and dose. Conclusion: The majority of the MI plants, according to the data, belonged to the Fabaceae (11%) and Asteraceae (9%) families, and the most prevalent natural components in plants with MI were flavonoids (43%), glucosides (25%), alkaloids (23%), phenolic acid (19%), saponins (15%), and tannins (12%).

1 June 2024 in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ARAarti Rajput
Aarti Rajput
RGRishabh Gaur
Rishabh Gaur
MKMayank Kulshreshtha
Mayank Kulshreshtha
SJSumedha Singh Jadaun
Sumedha Singh Jadaun
VKVibha Kumari
Vibha Kumari
Background: Emulgel combines the qualities of an emulsion with those of a gel. In order to create an emulgel w/o or o/w, emulsions have to be formulated, which are then com-bined with a gelling agent, resulting in a dual-control drug release. Celecoxib exhibits analge-sic, antipyretic and anti-inflammatory activities and is used to treat osteoarthritis, severe pain, rheumatoid arthritis, and other medical conditions. Methods: Celecoxib Emulgel was developed and evaluated by using natural oil and carbopol-940 as a gelling agent in different concentrations. The screening of various oils, co-surfactants and surfactants was performed to determine the solubility. The essential oils (eucalyptus oil and turpentine oil) were used as penetration modifiers. Studies on compatibility with polymers have been conducted, and the results indicate that there should be no physical or chemical interactions between the polymers and the drug substance. For the preparation of emulgel, various emulsions were prepared with Smix (cosurfactant and surfactant) ratios (1:1, 2:1 and 3:1). The selection of a gelling agent was done by incorporating the selected emulsion system ratio of 1:1 with the combinations of polymers carbapol 940, carbapol 934, and HPMC (0:1:0, 0:0.5:1, 0:0:3, 0.5:0:1, 1:0:0) gel base to make a homogenous emulgel. Results: The emulgel was examined visually to see if it had any phase behaviour, feel, spread-ability, and grittiness by applying its thin layer to a slide. Then, all six formulations of emulgel were prepared with the selected gelling agent. All emulgels were evaluated for pH, physical properties (consistency, homogeneity, colour, texture), drug content, spreadability, extrudabil-ity, swelling index, viscosity, stability and centrifugation. A Franz diffusion cell and an egg membrane were used to perform in-vitro drug release. Conclusion: Among all prepared formulations, EG1 had a better release, higher viscosity, higher drug content, and a higher swelling index than the others. The formulation EG1 showed higher drug release (91.25%) within 8 hours.

4 September 2026 in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
TVTushar Varshney
Tushar Varshney
SSSukhdev Sharma
Sukhdev Sharma
VKVibha Kumari
Vibha Kumari
MSManu Sharma
Manu Sharma
VKVivek Kumar
Vivek Kumar
Introduction: Bigel formulations are multifunctional two-phase systems that incorporate hydrogels and organogels in varying ratios, maximizing the functional advantages of the water and oil phases. Such a biphasic system addresses the drawbacks of monophasic gels, in which organogels enhance transdermal penetration while the hydrogel maintains adequate hydration of the stratum corneum. Methods: A hydrogel system was dispensed by gradually adding Carbopol 940 into distilled water while maintaining uniform stirring. For the preparation of organogels, Span 20 and Span 80 were incorporated into olive oil at an elevated temperature (60°C) with constant agitation. The final hydrogel and organogel bases were homogenized in varying proportions to obtain bigel formulations. The formulation was evaluated for parameters such as spreadability, extrudability, swelling behaviour, drug content, in vitro drug release profile, stability testing, and antimicrobial assessment. results: Among all batches, formulation B5 exhibited the highest drug release (80.81% at 6 hours) and demonstrated potent antimicrobial efficacy, as reflected by a zone of inhibition ranging from 17.43 ± 0.04 mm to 36.33 ± 1.15 mm against microbial strains. Result: The formulations were comprehensively evaluated for physicochemical characteristics such as spreadability, extrudability, swelling behaviour, viscosity, drug content, and stability upon centrifugation. Among the prepared batches, B5 showed the highest drug release (94.1% at 8 h) and displayed significant antimicrobial activity, producing zones of inhibition ranging from 17.43 ± 0.04 mm to 36.33 ± 1.15 mm against the tested microbial strains. Stability studies demonstrated their physicochemical properties throughout the three-month accelerated stability study, indicating robustness. Discussion: Effective topical administration against Candida albicans was demonstrated by the optimal release, stability, and antifungal activity of B5 optimized clotrimazole bigel. With all factors considered, outcomes suggest bigel-based administration as a feasible approach for enhancing local clotrimazole therapy while retaining high patient acceptability. Conclusion: Among the prepared batches, B5 showed the largest zone of inhibition (36.33 ± 1.15 mm) against Candida albicans, demonstrating the potential of the developed bigel as an effective topical treatment for cutaneous fungal infections.